Universal Flu Vaccine in Development: Adolfo Sastre on Targeting Conserved Regions of Influenza

Short Summary

In the NPR Short Wave episode, Regina Barber speaks with Adolfo Sastre, a viral immunologist at Mount Sinai, about a universal flu vaccine designed to guard against all influenza viruses by focusing on conserved regions rather than the virus changing year to year. The podcast explains how current vaccines cover three circulating strains of influenza A and B and why they must be updated annually due to viral mutation. It also outlines the phase one results, which show safety and induction of potentially protective antibodies, while phasing into phase two is stalled by funding constraints and the closure of NIH CIVIC funding. The interview conveys both scientific optimism and real world hurdles in bringing a universal flu vaccine to fruition.

• Concept of a universal flu vaccine centers on conserved viral regions rather than changing surface proteins.
• Phase one showed safety and antibody induction that may be protective, but phase two depends on funding.
• Current funding slowdowns and stability maintenance costs threaten progress toward trials.
• Scientist Adolfo Sastre remains cautiously optimistic about long term impact on public health.

Introduction to the Podcast Topic

The podcast discusses the persistent threat of flu viruses and the ongoing quest for a universal influenza vaccine. It opens by framing the scale of flu impact and the existence of more than one hundred potential pandemic flu viruses that could arise. The guest, Adolfo Sastre, is a viral immunologist at Mount Sinai who is developing a vaccine that could provide broad protection against all influenza strains by targeting conserved elements of the virus. The conversation then shifts to the biology of flu viruses, the reason vaccines must be updated annually, and how a universal vaccine would differ from current strategies.

Influenza Biology and Current Vaccine Strategy

The discussion explains that human influenza involves three main virus types: influenza A with two main subtypes H1 and H3, and influenza B. The vaccine is designed as a trivalent or tricomponent formulation to cover these circulating strains, but the virus mutates each year in ways that can render parts of the vaccine less effective. The host explains that vaccines traditionally target parts of the virus that change, which is why predictions about circulating strains are essential for vaccine design. When a new strain emerges that is not well covered by the vaccine, efficacy can drop significantly.

The Universal Vaccine Concept: Conserved Regions

A core idea presented is that a universal flu vaccine would need to focus on regions of the virus that remain conserved across strains and over time. The interview uses an accessible analogy to illustrate the concept: the virus is like a cow, and protective regions are parts whose disruption would prevent damage without relying on areas that frequently mutate. The challenge is identifying conserved regions that elicit a robust protective immune response. The guest emphasizes that not every conserved region is protective, so researchers must discover which conserved areas can induce effective immunity and then design a vaccine to target those regions differently from current vaccines.

Phase 1 Trial: Safety and Immunogenicity

On the clinical side, the conversation reveals that phase one trials primarily assess safety and whether the vaccine elicits a favorable immune response. For this universal vaccine candidate, the phase one results showed induction of antibodies at levels believed to be protective. While these results do not prove protection in humans yet, they are a positive signal that the target immune responses can be achieved. The team has not yet started phase two trials, as funding has become a major obstacle rather than a lack of scientific progress.

Barriers to Phase Two and Funding Realities

The discussion delves into why phase two has not commenced. The primary bottleneck is money, with phase two clinical trials and the maintenance of a stability program for prepared vaccine material requiring substantial funding. The NIH program CIVIC, which supported improved influenza vaccines, has been paused, and there is no current call for new proposals. This creates a potential one to two year funding gap, during which the vaccine materials must be kept stable, which itself costs money. The guest notes that the broader context of NIH budgeting and contracting changes further complicates timely renewal and progress.

Impact on Researchers and Optimism for the Future

The interview captures the emotional tension between scientific possibility and funding constraints. The researcher expresses frustration but also determination, suggesting that funding will need to align with the discovery process to translate this vaccine concept into a practical public health tool. The guest remains optimistic about the long term potential of universal vaccines, arguing that advancing new mechanisms and understanding the conserved regions can provide benefits for humanity even if immediate clinical translation is delayed. The conversation closes with appreciation for the scientific process and a call to continue pursuing credible, transformative solutions in vaccine technology.

Concluding Thoughts and Further Reading

The episode ends by pointing listeners toward additional content on vaccine development and clinical trials, underscoring NPR's commitment to science storytelling and the ongoing evolution of vaccine science.